BMI View: It is vital that companies that are looking to sell non-communicable disease therapeutics work
alongside the public sector and focus on physician education and patient awareness in a market that has
traditionally focussed on infectious diseases such as malar ..."
BMI View: Many emerging market economies are increasingly exposed to the negative effect of sustained
lower commodity prices. This is putting downward pressure on government finances and, as a consequence,
healthcare budgets. We nevertheless maintain a positive long-t ..."
BMI View: Drugmaker revenue earning opportunities in Kenya will continue to be restricted. Some
progress has been made towards addressing equity challenges, but universal coverage - and subsequently a
decline in the reliance of out-of-pocket spending - will not be ach ..."
BMI View: While Kenya's underdeveloped healthcare infrastructure is not conducive to clinical trials (only
14 clinical trials were registered in 2014), the country, as with other markets in the region, can offer
numerous benefits to drugmakers looking to conduct clini ..."
BMI View: Our outlook for Kenya's pharmaceutical expenditure is positive and will be driven by expanding
national health insurance coverage and improving public healthcare provision. While the Kenyan
government is focused on improving its population's access to health ..."
BMI View: While the Kenyan government is focused on improving its population's access to healthcare,
drugmakers and medical device companies looking for a rapid return on investment will face challenges.
Inefficiencies such as the lack of suitable infrastructure and d ..."
BMI View: The rising non-communicable disease burden will boost demand for prescription medicines to
treat chronic diseases in Kenya. However, we believe drugmakers cannot employ their developed state
business models to market medicines in a country that has tradition ..."
Kenya Pharmaceuticals & Healthcare Report
A high birth rate due to limited birth control and the importance placed on having a large family by rural populations as a source of economic strength, as well as a growing disease burden, is likely to put further pressure on Keny ..."
BMI View: Investment into Kenya's healthcare sector by pharmaceutical and medical device companies is
an advisable business strategy - as highlighted by the high growth forecast in healthcare spending between
2013 and 2018. However, we note that there are downside ris ..."
BMI View: The growing Kenyan population will support the growth of the country's pharmaceuticals and
healthcare industry. While fertility rates have dropped over the last decade, from 5.0 births per woman in
2003 to 4.4 births per woman in 2013, we note that these fig ..."